Volume 6 Supplement 3

Fifth Annual Research Conference: Innovation from Cell to Society

Open Access

CD34 function in intracellular signaling and mucosal inflammatory disease development

  • Matthew Gold1Email author,
  • Marie-Renee Blanchet1,
  • Lionel A Samayawardhena2,
  • Jami Bennett1,
  • Steven Maltby1,
  • Catherine J Pallen2 and
  • Kelly M McNagny1
Allergy, Asthma & Clinical Immunology20106(Suppl 3):P15

https://doi.org/10.1186/1710-1492-6-S3-P15

Published: 26 November 2010

Objective/purpose

CD34 is a cell surface sialomucin that has been the subject of extensive interest, largely based on its use as a marker for hematopoietic stem cells (HSCs) and vascular endothelia. Despite the almost ubiquitous use of CD34 as a HSC marker, little is known about its cellular function. Our lab was the first to show that CD34 is also highly expressed on mature murine mast cells, and we and other groups have found it to be expressed on eosinophils and dendritic cells. We found that mast cells derived from Cd34 -/- mice exhibit a marked increase in cell-cell aggregation. Moreover, when Cd34 -/- mice were challenged in a mouse model of asthma, immune cell accumulation in the lung was drastically reduced, while the number of immune cells in the lung at baseline was similar to that of their wild-type counterparts. We have since found that deletion of the Cd34 gene in mice renders these animals resistant to a wide range of other mucosal inflammatory diseases, including hypersensitivity pneumonitis (HP), ulcerative colitis, salmonella infection and intestinal tumor development. Our objectives are to examine the specific role of CD34 in cellular function and to see whether or not CD34 is a viable therapeutic target to treat mucosal inflammatory diseases.

Methods

Bone marrow mast cells were derived from wild-type and Cd34 -/- mice after four week culture in media containing IL-3. Changes in migration, polarization, degranulation and cytokine production were measured after c-kit and/or FceRI stimulation. For in vivo studies, we developed transgenic mice that lack the mouse Cd34 gene and instead express, in all the appropriate tissues, the human Cd34 gene. These mice were put through a standard Ovalbumin (OVA) induced asthma model. Airway inflammation severity was assessed by analysis of the broncho-alveolar lavage (BAL) content, histological scoring of H&E stained lung sections and cytokine production of isolated lung inflammatory cells in response to OVA.

Findings

Preliminary experiments have suggested that CD34 plays an important role in c-kit signaling events and FceRI induced degranulation. Initial testing of our hCd34 tg mice has shown that expression of the human Cd34 gene in CD34-deficient mice is sufficient to regain susceptibility to both allergic asthma and HP in mouse CD34-deficient animals. These findings suggest that human CD34 serves a similar function to mouse CD34 in both animal disease models.

Deliverables and relevance

We show that in mast cells, CD34 plays an important role in regulating cellular signaling through both the c-kit and FceRI pathways. In addition, we have demonstrated that expression of human CD34 serves a similar function to mouse CD34 in both asthma and HP, providing a proof-of-concept to assess therapeutics targeting human CD34 in hCd34 tg mice as a humanized mouse model to treat these diseases. Allergic asthma affects more than 10% of all North Americans and is a major cause of hospitalization of children. Current therapeutics are largely ineffective for chronic asthma and the most potent therapies can carry a number of side effects. CD34 could represent a new therapeutic target, and since we have shown that CD34 plays a role in the susceptibility to a wide range of mucosal inflammatory diseases, it is likely that it could serve as a viable treatment for a number of diseases.

Authors’ Affiliations

(1)
The Biomedical Research Centre, University of British Columbia
(2)
The Child & Family Research Institute, University of British Columbia

Copyright

© Gold et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement